Showing results (1-10 of 100) with videos related to
Sort By:
Pageof 10
Expert Opinion on Pharmacotherapy|August 30, 2013
Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendationsIbrahim C HaznedarogluMediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)Ibrahim C HaznedarogluExpert Opinion on Pharmacotherapy|May 8, 2013
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatmentIbrahim C HaznedarogluMediterranean Journal of Hematology and Infectious Diseases|March 7, 2015
Drug Therapy in the Progressed CML Patient with multi-TKI FailureIbrahim C HaznedarogluAdvances in Experimental Medicine and Biology|February 4, 2021
Protein Kinases in Hematological DisordersMufide Okay, Ibrahim C HaznedarogluClinical Science (London, England : 1979)|November 20, 2012
Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesisIbrahim C Haznedaroglu, Yavuz BeyazitJournal of the Renin-Angiotensin-Aldosterone System : JRAAS|September 3, 2010
Pathobiological aspects of the local bone marrow renin-angiotensin system: a reviewIbrahim C Haznedaroglu, Yavuz BeyazitOpen Medicine (Warsaw, Poland)|January 8, 2019
Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid LeukemiaUmit Y Malkan, Ibrahim C HaznedarogluThe International Journal of Biochemistry & Cell Biology|April 5, 2003
Towards the understanding of the local hematopoietic bone marrow renin-angiotensin systemIbrahim C Haznedaroglu, M Akif OztürkThe International Journal of Biochemistry & Cell Biology|October 21, 2005
Rethinking leptin and insulin action: therapeutic opportunities for diabetesBulent O Yildiz, Ibrahim C HaznedarogluPageof 10